EcoDrugPlus

Nitric Oxide Synthase 2

Ensembl ID : ENSDLEG00000006215
Gene Symbol: NOS2
3 Cross references
166 Possible Orthologues:

Notch Receptor 1

Ensembl ID : ENSDLEG00000016186
Gene Symbol: NOTCH1
3 Cross references
269 Possible Orthologues:

Notch Receptor 3

Ensembl ID : ENSDLEG00000006449
Gene Symbol: NOTCH3
1 Cross references
201 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSDLEG00000001502
Gene Symbol: NFKB1
3 Cross references
205 Possible Orthologues:

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSDLEG00000010672
Gene Symbol: NFKB2
3 Cross references
124 Possible Orthologues:

Nuclear Factor, Erythroid 2 Like 2

Ensembl ID : ENSDLEG00000009266
Gene Symbol: NFE2L2
3 Cross references
216 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSDLEG00000002003
Gene Symbol: NR1H2
3 Cross references
304 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSDLEG00000013403
Gene Symbol: NR1H3
3 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSDLEG00000011975
Gene Symbol: NR1H4
3 Cross references
388 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSDLEG00000003062
Gene Symbol: NR3C1
3 Cross references
280 Possible Orthologues:

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSDLEG00000015618
Gene Symbol: NR3C2
3 Cross references
214 Possible Orthologues:

Nucleotide Binding Oligomerization Domain Containing 2

Ensembl ID : ENSDLEG00000004464
Gene Symbol: NOD2
1 Cross references
167 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).